[Lifeline, A Musical That Raises The Alarm On Antimicrobial Resistance](https://wbbsec.com/opinions-and-features/lifeline-a-musical-that-raises-the-alarm-on-antimicrobial-resistance/)
[Lifeline, A Musical That Raises The Alarm On Antimicrobial Resistance](https://wbbsec.com/opinions-and-features/lifeline-a-musical-that-raises-the-alarm-on-antimicrobial-resistance/)
In: Press Releases

For Immediate Release

January 12, 2022

Cranford, NJ– Steve Brozak, DMH, President of WBB Securities today participated in a Biotech Showcase session titled, Covid: What Happens Next?  The session content drew from a report he and Richard Marfuggi, MD prepared at the request of the Foreign Policy Association that was published simultaneously with Biotech Showcase.  The report, titled Omicron:  What Happens Next? addresses eight important issues surrounding SARS-CoV-2 virus and Covid-19 disease.  They are  the impact and longevity of Covid, why and how Coronavirus was first discovered in South Africa, the realities of herd immunity and vaccine protections, a brief primer on how the human immune system responds to vaccine and infection, an explanation of the origins and impact of variants, what lies ahead, future vaccines and treatments, and a call to action for surveillance, detection adequate treatment and targeted vaccines. 

To read the article from the Foreign Policy Association, please click here…

About WBB Securities.

WBB Securities is a leading Investment Management, Investment Banking, and Equity Research firm focused primarily in the life sciences niche. Established in 2001 with offices in New Jersey, New York, and California. WBB Securities is registered with the SEC as a broker-dealer, a member of FINRA, and a state-registered investment advisor with a proprietary trading desk. The firm is comprised of a nationwide team of respected senior investment and research professionals serving institutional and high-net-worth clients.

www.wbbsec.com 

About Biotech Showcase

Biotech Showcase is the investor and partnering conference for private, small- and mid-cap biotech companies. The event is organized by the EBD Group, which organizes a family of international partnering events to create a dynamic marketplace where thousands of industry professionals meet one-to-one to discuss in- and out-licensing of assets, strategic collaborations and financial investment. Each year EBD events generate more than 50,000 one-to-one meetings.

https://informaconnect.com/biotech-showcase/